S0820, Adenoma and Second Primary Prevention Trial
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Research Base: Southwest Oncology Group
NCT ID: NCT01349881
NCI Protocol Number: SWOG-S0820
For more information see ClinicalTrials.gov
Eflornithine placebo & sulindac placebo; Eflornithine & sulindac placebo; Eflornithine placebo & sulindac; Eflornithine plus sulindac